Cited 17 times in
Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이하영 | - |
dc.contributor.author | 임승택 | - |
dc.contributor.author | 홍수정 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 한정우 | - |
dc.date.accessioned | 2014-12-19T16:37:23Z | - |
dc.date.available | 2014-12-19T16:37:23Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89877 | - |
dc.description.abstract | PURPOSE: The combination of gemcitabine and docetaxel (GD) is used to effectively treat patients with soft tissue sarcoma (STS). It is widely considered that the conventional doses used are too high for long term use and many patients must discontinue GD treatment due to its toxicity. Therefore, to determine the appropriate dose meeting acceptable efficacy results, while minimizing toxic side effects, we treated patients with a weekly infusion of GD (weekly GD). MATERIALS AND METHODS: A total of 22 patients presenting a variety of STSs were treated at Yonsei Cancer Center. All patients had metastatic or recurrent cancer and had previously received doxorubicin and ifosfamide combination chemotherapy. In all cases, gemcitabine (1,000 mg/m(2)) and docetaxel (35 mg/m(2)) were administered intravenously on days 1 and 8 of a 21-day cycle. We retrospectively reviewed the medical records of these patients. RESULTS: The response rate was 4.5%, with one patient diagnosed with leiomyosarcoma having a partial response, and the disease control rate was 40.9%. The median progression-free survival (PFS) duration was 2.7 months and the PFS was correlated with the treatment response to a weekly GD. The median overall survival (OS) duration was 7.8 months and the OS was correlated with histology. There was no significant difference in OS between patients who received weekly GD as a 2nd line chemotherapy and those who received 3rd line or more. Treatment was generally well tolerated. CONCLUSION: Weekly GD was well tolerated and showed moderate efficacy, indicating that this could be a reasonable option as a salvage treatment for metastatic STS. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Ha-young Lee | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Soo Jung Hong | - |
dc.contributor.googleauthor | Jung Woo Han | - |
dc.contributor.googleauthor | Seung Taek Lim | - |
dc.contributor.googleauthor | Jae Kyung Roh | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.identifier.doi | 10.4143/crt.2012.44.1.43 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03271 | - |
dc.contributor.localId | A03380 | - |
dc.contributor.localId | A04410 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A04324 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 22500160 | - |
dc.subject.keyword | Docetaxel | - |
dc.subject.keyword | Gemcitabine | - |
dc.subject.keyword | Refractory soft-tissue sarcoma | - |
dc.subject.keyword | Weekly | - |
dc.contributor.alternativeName | Lee, Ha Young | - |
dc.contributor.alternativeName | Lim, Seung Taek | - |
dc.contributor.alternativeName | Han, Jung Woo | - |
dc.contributor.alternativeName | Hong, Soo Jung | - |
dc.contributor.alternativeName | Kim, Hyo Song | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Lee, Ha Young | - |
dc.contributor.affiliatedAuthor | Lim, Seung Taek | - |
dc.contributor.affiliatedAuthor | Hong, Soo Jung | - |
dc.contributor.affiliatedAuthor | Kim, Hyo Song | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Han, Jung Woo | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 44 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 43 | - |
dc.citation.endPage | 49 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.44(1) : 43-49, 2012 | - |
dc.identifier.rimsid | 31959 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.